Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Posaconazole for Primary Antifungal Prophylaxis in AML Patients: A Real Life Single Center Experience and a Comparison with the Historical Cohort

Paola Minetto, MD, Fabio Guolo, MD, Malgorzata Mikulska, MD, Giordana Pastori, MD, Livia Giannoni, MD, Elisa Furfaro, Franca Miletich, Valerio Del Bono, MD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Roberto Lemoli, MD, Claudio Viscoli, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 5255.

https://doi.org/10.1182/blood.V124.21.5255.5255

Published: 2014

Journal Articles

SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study

Thomas G Martin, III, MD, Stephen A. Strickland, MD, MSCI, Martha Glenn, MD, Wei Zheng, PhD, Nikki Daskalakis, MD, Joseph R. Mikhael, MD

Blood (2013) 122 (21): 284.

https://doi.org/10.1182/blood.V122.21.284.284

Published: 2013

Journal Articles

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Paul G. Richardson, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD, PhD, Marc S Raab, Thierry Facon, MD, Ravi Vij, MBBS, Darrell J. White, MD, Donna Reece, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Wei Deng, Glenn Kroog, MD, Anil K Singhal, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 202.

https://doi.org/10.1182/blood.V120.21.202.202

Published: 2012

Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2011) 118 (21): 248.

https://doi.org/10.1182/blood.V118.21.248.248

Published: 2011

Journal Articles

Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,

Sundar Jagannath, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, Thierry Facon, MD, Ravi Vij, MD, Marc S Raab, MD, PhD, Darrell J. White, MD, Min-Hui Wang, PhD, Teresa Parli, MD, Blake J Bartlett, PhD, Anil K Singhal, MD, Paul G. Richardson, MD

Blood (2011) 118 (21): 3968.

https://doi.org/10.1182/blood.V118.21.3968.3968

Published: 2011

Journal Articles

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MD, Philippe Moreau, MD, Donna E. Reece, MD, FRCPC, Darrell J. White, MD, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Jean-Francois Rossi, MD, PhD, Claire Tsao, Teresa Parli, Glenn Kroog, MD, Anil K Singhal, Paul G. Richardson, MD

Blood (2011) 118 (21): 303.

https://doi.org/10.1182/blood.V118.21.303.303

Published: 2011

Journal Articles

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, MD, Philippe Moreau, MD, Andrzej J Jakubowiak, MD, PhD, Thierry Facon, MD, Sundar Jagannath, MD, Ravi Vij, MD, Donna E Reece, MD, Darrell J White, MD, Marc S Raab, MD, PhD, Lotfi Benboubker, MD, PhD, Jean-Francois Rossi, MD, PhD, Claire Tsao, PhD, John Fry, David Berman, MD, PhD, Anil K Singhal, MD, Sagar Lonial, MD

Blood (2010) 116 (21): 986.

https://doi.org/10.1182/blood.V116.21.986.986

Published: 2010

Journal Articles

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Alan Wayne, MD, Deepa Bhojwani, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PHD, Lewis B. Silverman, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 3246.

https://doi.org/10.1182/blood.V116.21.3246.3246

Published: 2010

Journal Articles

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Robert J. Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H. Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 2516.

https://doi.org/10.1182/blood.V116.21.2516.2516

Published: 2010

Journal Articles

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert Lechleider, MD, Karen Kaucic, MD, Ira Pastan, MD

Blood (2009) 114 (22): 888.

https://doi.org/10.1182/blood.V114.22.888.888

Published: 2009

Journal Articles

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Alan S. Wayne, MD, Deepa Bhojwani, MD, Sima Jeha, MD, Maryalice Stetler-Stevenson, MD, PhD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, Robert J Kreitman, MD, Karen Kaucic, MD, Ira Pastan

Blood (2009) 114 (22): 839.

https://doi.org/10.1182/blood.V114.22.839.839

Published: 2009

Journal Articles

The Effect of the Interaction between Proton Pump Inhibitors (PPI) and Tyrosine Kinase Inhibitors (Imatinib, Nilotinib and Dasatinib).

Piera La Cava, PhD, Annalisa Chiarenza, MD, Daniele Tibullo, PhD, Cesarina Giallongo, PhD, Alessandra Romano, MD, Fabio Stagno, MD, Giuseppe A. Palumbo, MD, Francesco Di Raimondo, MD

Blood (2007) 110 (11): 2957.

https://doi.org/10.1182/blood.V110.11.2957.2957

Published: 2007

Journal Articles

A Community Cancer Center Experience of the Efficacy and Safety of the Use of Intravenous Iron Dextran in Chemotherapy Induced Anemia.

Kaushik Sen, MD, Ngozi O. Okoro, MD, Theresa R. Hedman, RN

Blood (2004) 104 (11): 3676.

https://doi.org/10.1182/blood.V104.11.3676.3676

Published: 2004

Journal Articles

An Antibody From a Patient With Ranitidine-Induced Thrombocytopenia Recognizes a Site on Glycoprotein IX That Is a Favored Target for Drug-Induced Antibodies

G. Gentilini, B.R. Curtis, R.H. Aster

Blood (1998) 92 (7): 2359–2365.

https://doi.org/10.1182/blood.V92.7.2359

Published: 1998

NARROW

Posaconazole for Primary Antifungal Prophylaxis in AML Patients: A Real Life Single Center Experience and a Comparison with the Historical Cohort

SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

The Effect of the Interaction between Proton Pump Inhibitors (PPI) and Tyrosine Kinase Inhibitors (Imatinib, Nilotinib and Dasatinib).

A Community Cancer Center Experience of the Efficacy and Safety of the Use of Intravenous Iron Dextran in Chemotherapy Induced Anemia.

An Antibody From a Patient With Ranitidine-Induced Thrombocytopenia Recognizes a Site on Glycoprotein IX That Is a Favored Target for Drug-Induced Antibodies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only